TY - JOUR AU - Quintela-Fandino, Miguel AU - Holgado, Esther AU - Manso, Luis AU - Morales, Serafin AU - Bermejo, Begoña AU - Colomer, Ramon AU - Apala, Juan V. AU - Blanco, Raquel AU - Muñoz, Manuel AU - Caleiras, Eduardo AU - Iranzo, Vega AU - Martinez, Mario AU - Dominguez, Orlando AU - Hornedo, Javier AU - Gonzalez-Cortijo, Lucia AU - Cortes, Javier AU - Gasol Cudos, Ariadna AU - Malon, Diego AU - Lopez-Alonso, Antonio AU - Moreno-Ortíz, María C. AU - Mouron, Silvana AU - Mañes, Santos PY - 2020 DA - 2020/11/11 TI - Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial JO - Breast Cancer Research SP - 124 VL - 22 IS - 1 AB - Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after bevacizumab monotherapy for advanced HER2-negative breast cancer. SN - 1465-542X UR - https://doi.org/10.1186/s13058-020-01362-y DO - 10.1186/s13058-020-01362-y ID - Quintela-Fandino2020 ER -